News for Evotec SE (EVOTF)

U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Wednesday. Shares of DHT Holdings, Inc. DHT fell sharply in pre-market ...

RBC Capital analyst Charles Weston has updated his price target for Evotec (EVO), increasing it from EUR 11.60 to EUR 11.90. Despite the adjustment, the analyst

Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations.The col

Evotec SE (NASDAQ: EVO) secures a $2.5 million grant from The Gates Foundation for TB treatment development. The funding reinforces a successful five-ye

Group Revenue: EUR200 million, a 4% decrease versus Q1 2024.Shared R&D Revenue: EUR140.6 million, down from EUR155.2 million in Q1 2024.Just Evotec Biologics R

May 06, 2025 / 12:00PM GMTOperator Ladies and gentlemen, welcome to the Evote SE quarterly statement Q1 2025 conference call. I am George, the Chorus Call opera

Evotec SE (NASDAQ:EVO) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ETCompany ParticipantsVolker Braun - Head, Investor RelationsChristian...

The major U.S. index futures are currently pointing to an extended pullback on Wall Street on Tuesday, with stocks likely to see further downside after ending Monday's volatile session mostly lower.

European stocks were broadly lower on Tuesday as investors assessed the latest batch of earnings and awaited upcoming Fed and BoE meetings. The euro was marginally higher against the dollar as trade negotiations returned to the spotlight.

European stocks were broadly lower on Tuesday as investors assessed the latest batch of earnings and awaited upcoming Fed and BoE meetings. The euro was marginally higher against the dollar as trade negotiations returned to the spotlight.

Group revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just - Evotec Biologics with continuing growth momentumStrong pro

Evotec SE (EVO) reports Q1 2025 revenues of €200 million, a 4% decline year-over-year but slightly ahead of internal forecasts. The Just - Evotec Biol

Evotec SE (EVO) is set to release its Q1 2025 earnings on May 6, 2025. The consensus estimate for Q1 2025 revenue is $244.94 million, and the earnings are expec

HAMBURG, DE / ACCESS Newswire / April 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its inter

Evotec SE (EVO) to announce Q1 2025 financial results on May 6, 2025. Conference call scheduled at 2:00 PM CEST to discuss earnings and business updates

Deutsche Bank has revised its rating for Evotec (EVO), upgrading the stock from a "Sell" to a "Hold" recommendation. Additionally, the bank increased its price

Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needsPerformance-based and program-based payments of in

Evotec SE (NASDAQ:EVO) received a milestone payment of $75 million from Bristol Myers Squibb. The collaboration focuses on developing molecular glue deg

Group Revenue: EUR797 million, a 2% increase versus 2023.Shared R&D Revenue: Declined from EUR673 million in 2023 to EUR611 million in 2024.Just - Evotec Biolo